Trial Profile
Randomized trial of olmesartan and azelnidipine for treatment of hypertension with chronic kidney disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Azelnidipine
- Indications Hypertension; Kidney disorders
- Focus Therapeutic Use
- Acronyms BECOME-J
- 30 Mar 2016 Status changed from recruiting to completed.
- 21 Dec 2011 New trial record